Allon Therapeutics, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2012. The company reported a net loss of $1,847,863 or $0.01 per share for the three months ended September 30, 2012, compared to a net loss of $2,983,887 or $0.04 per share for the three months ended September 30, 2011, representing a decrease in net loss of $1,136,024.

For the nine months ended September 30, 2012, the company reported a net loss of $7,869,780 or $0.07 per share, compared to a net loss of $8,877,797 or $0.11 per share for the nine months ended September 30, 2011.